Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Claudin-18.2 is a promising target for gastric cancer (GC) therapy. Targeted drugs and immunotherapies show high efficacy and safety in clinical trials, offering new hope for GC patients.
Area Of Science
- Oncology
- Molecular Biology
- Gastroenterology
Background
- Claudin-18.2 (CLDN18.2) is a tight junction protein crucial for gastric homeostasis.
- CLDN18.2 expression is restricted to the stomach, making it a specific biomarker for gastric cancer (GC).
Purpose Of The Study
- To review the role of CLDN18.2 as a biomarker in GC.
- To discuss CLDN18.2-targeted therapies and their clinical applications.
Main Methods
- Narrative review of existing literature and clinical trial data.
- Analysis of preclinical and clinical evidence for CLDN18.2-targeted agents.
Main Results
- CLDN18.2-targeted therapies, including monoclonal antibodies (mABs) and CAR-T cell immunotherapies, demonstrate significant potential.
- Ongoing clinical trials worldwide are evaluating these novel treatments for GC.
Conclusions
- CLDN18.2 is a validated therapeutic target for gastric cancer.
- Targeted therapies against CLDN18.2 show promising efficacy and safety profiles, advancing GC treatment strategies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
Saliva and Diagnostics
Saliva is a watery substance secreted by the salivary glands into the mouth. Human saliva contains 99.5% water with electrolytes, mucus, white...